HAMBURG, Germany, May 11, 2011 /PRNewswire/ -- In response to the growing interest in the sensitive blood-test for thedetection of tumor-specific DNA-molecules, Inostics GmbH (Hamburg, Germany) has founded a US subsidiary. Inostics' non-invasive test based on the BEAMing-Technology is one of the most sensitive methods available today
Located within state-of-the-art-laboratories at The Science & Technology Park at Johns Hopkins in Baltimore, MD, Inostics Inc. will be headed by Dan Edelstein, MBA who has extensive experience from the Ludwig Center for Cancer Genetics and Therapeutics.
Inostics GmbH is a biotech-company working in the field of cancer molecular genetics. At present, Inostics GmbH serves as a contract research organization for pharmaceutical companies and supports the development of new oncology drugs. Inostics' field of expertise is the highly sensitive detection of tumor-specific genetic changes, such as gene mutations, in plasma/serum and tissues samples. Inostics was founded in 2008 in Hamburg, by Indivumed GmbH, and scientists of the Johns Hopkins University in Baltimore.
For further information please visit http://www.inostics.com or write at firstname.lastname@example.org. Germany: USA: Inostics GmbH Inostics Inc. Contact: Frank Diehl, Ph.D. Contact: Dan Edelstein, MBA Centrum fuer Innovative Medizin Science & Technology Park at Johns Hopkins Falkenried 88 855 N. Wolfe Street, Suite 631 D-20251 Hamburg, Germany Baltimore, MD 21205, US Tel.: +49(0)40-413383-90 Tel.: +1-443-759-8650 Fax: +49(0)40-413383-99 Fax: +1-443-455-1636 Email: email@example.com Email: firstname.lastname@example.org
SOURCE Inostics GmbH
Subscribe to our Free Newsletters!